Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Accumulated Expenses (2019 - 2025)

China Pharma Holdings' Other Accumulated Expenses history spans 7 years, with the latest figure at $1.9 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 20.91% year-over-year to $1.9 million; the TTM value through Dec 2025 reached $1.9 million, up 20.91%, while the annual FY2025 figure was $1.9 million, 20.91% up from the prior year.
  • Other Accumulated Expenses reached $1.9 million in Q4 2025 per CPHI's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2021 to a low of $24000.0 in Q3 2024.
  • Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $2.3 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 97.84% in 2024, then soared 6614.61% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $2.8 million in 2021, then decreased by 10.93% to $2.5 million in 2022, then crashed by 49.29% to $1.3 million in 2023, then rose by 26.44% to $1.6 million in 2024, then grew by 20.91% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Other Accumulated Expenses are $1.9 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025).